Duration of GLP-1 Receptor Agonist Therapy

Guideline-Directed Treatment Evolution

The American Diabetes Association recommends that no single medication or combination has demonstrated durable effects, and for many patients, injectable medications become necessary within 5-10 years of diabetes diagnosis, often requiring progression beyond GLP-1 monotherapy 1
The American Diabetes Association suggests that when patients fail to maintain glycemic targets on GLP-1 therapy, treatment intensification with SGLT2 inhibitors, basal insulin, or prandial insulin is recommended 1
Regular review of therapy response is mandated by the American Diabetes Association, with consideration to stop or reduce doses if minimal benefits exist or harm outweighs benefit 1

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend GLP-1 receptor agonists as preferred add-on therapy in patients with chronic kidney disease (CKD) who are not achieving glycemic targets on metformin and/or SGLT2 inhibitors 2
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that patients with CKD may continue GLP-1 receptor agonist therapy longer due to cardiovascular and kidney protective benefits beyond glucose lowering 2
No dose adjustment is required for most GLP-1 agents (dulaglutide, liraglutide, semaglutide) across CKD stages, facilitating continued use, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 2

The American Diabetes Association recommends continuing GLP-1 therapy when HbA1c remains above individualized target and patient tolerates medication 1
The American Diabetes Association suggests continuing GLP-1 therapy when cardiovascular or kidney disease is present (liraglutide, dulaglutide, or injectable semaglutide preferred for CV benefits) 2
The American Diabetes Association recommends considering discontinuation or dose reduction when HbA1c falls substantially below individualized target (e.g., <6.5% or 48 mmol/mol) 1
The American Diabetes Association suggests intensifying or switching therapy when glycemic targets are not met after 3-6 months of optimal GLP-1 dosing 1
The American Diabetes Association recommends intensifying or switching therapy when treatment failure occurs at 3-4 years (add basal insulin, SGLT2 inhibitor, or switch to combination therapy) 1